Novo to pay nearly $60M to settle Victoza marketing suits with DOJ, whistleblowers
admin 6th September 2017 Uncategorised 0Novo Nordisk just won a nod from the FDA for the cardiovascular risk reduction of Victoza, which should further propel sales of the blockbuster. But in a nod to a darker side of its sales history, the company has settled, for nearly $60 million, another batch of lawsuits over past marketing of the Type 2 diabetes drug.
More: Novo to pay nearly M to settle Victoza marketing suits with DOJ, whistleblowers
Source: fierce